Physician profile
Charles E Reed
NPI 1013919604
$13,062.93
in general payments reported to CMS, 2019-2025
43 companies · $1,870 in 2025
The $1,870 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,061 · 2020: $1,709 · 2021: $2,174 · 2022: $2,178 · 2023: $1,582 · 2024: $1,487 · 2025: $1,870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,920 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,920.10 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,555.37 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,442.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,240.35 | 2021-2025 | |
| Lilly USA, LLC | $958.43 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $821.91 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $657.93 | 2019-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $652.53 | 2019-2025 | Jardiance, Synjardy |
| Janssen Pharmaceuticals, INC | $639.90 | 2019-2022 | |
| Esperion Therapeutics, INC. | $488.28 | 2020-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $447.56 | 2019-2024 | Verquvo, Gardasil 9, Vaxneuvance |
| Novartis Pharmaceuticals Corporation | $416.30 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $405.14 | 2022-2025 | Rexulti, Nuedexta |
| Takeda Pharmaceuticals U.S.A., INC. | $392.98 | 2019-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $376.12 | 2022-2025 | |
| Avanir Pharmaceuticals, INC. | $310.02 | 2019-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.